Clinical Cancer Research, Vol 2, Issue 1 187-199, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme

AC Scheck, JR Shapiro, SW Coons, SA Norman and PC Johnson
Neuro-Oncology Research and Division of Neuropathology, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA. ascheck@mha.chw.edu

We and others have reported that human malignant gliomas demonstrate intratumor heterogeneity in which many regions may be benign; however, the presence of regions of increased malignancy in these same tumors is generally indicative of poor patient prognosis. These data suggested that tumor progression may be a local phenomenon, resulting in regions that progress to a more malignant type prior to the progression of the entire tumor. Implicit in this premise is the idea that molecular markers of tumor progression may be detectable prior to histological evidence of progression. This report details analyses performed on a primary and recurrent tumor obtained from the same patient in which the primary tumor was of a higher histological grade than the recurrent tumor. Results of molecular, cytogenetic, flow cytometric, and histological analyses of the primary tumor were indicative of a grade 4 glioblastoma multiforme. Standard cytogenetic and flow cytometric analyses demonstrated that the cells were near-diploid with a stem line population of 46,XX normal G-banded karyotypes. In contrast, tissue resected from the recurrent tumor 5 months later was histologically less malignant; however, the molecular, cytogenetic, and flow cytometric analyses of this sample demonstrated the presence of specific genetic abnormalities typically found in more malignant tumors. These data demonstrate that specific molecular and/or genetic changes leading to tumor progression may become detectable in a glioma prior to the appearance of histological features of a higher grade tumor.

This article has been cited by other articles:

				C. E. Eyler and J. N. Rich Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis J. Clin. Oncol., June 10, 2008; 26(17): 2839 - 2845. [Abstract] [Full Text] [PDF]

				W. K. Pfisterer, N. C. Hank, M. C. Preul, W. P. Hendricks, J. Pueschel, S. W. Coons, and A. C. Scheck Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas Neuro-oncol, October 1, 2004; 6(4): 290 - 299. [Abstract] [PDF]

				W. R. Shapiro Current Therapy for Brain Tumors: Back to the Future Arch Neurol, April 1, 1999; 56(4): 429 - 432. [Abstract] [Full Text] [PDF]